Table 3.

Predictors of mortality in LT recipients with COVID-19.

Study, year	Origin	Patients (n)	Risk-factors of mortality	Comments
Becchetti et al., 2020	Europe	57	History of previous or active cancer, such as being transplanted for HCC. Having cancer at COVID-19 diagnosis	Patients infected early after liver transplantation did not have a worse outcome
Webb et al., 2020	18 countries	151	Advanced age Increased baseline creatinine concentration Presence of non-liver cancer Presence of comorbidities	The type of immunosuppressants used and the time from transplantation were not independently associated with mortality.
Belli et al., 2021	Europe	243	Advanced age Serum creatinine >2 mg/dL, (trend)	Neither a specific comorbidity nor a combination of comorbidities emerged as independently associated with death. Use of TAC was confirmed as independently associated with a reduced mortality risk
Colmenero et al., 2021	Spain	111	Older age, male gender, increased comorbidities, raised D-dimer, serum ferritin and lymphocytopenia were associated with severe COVID-19	Adjusted mortality rates in patients older than 60 were similar in LT recipients and in the general population
Dumortier et al., 2021	France	91	Age Serum baseline creatinine (trend)	Independent risk factors for severe disease: dyspnea and fever

HCC: hepatocellular carcinoma; LT: liver transplantation; TAC: Tacrolimus